GLAXOSMITHKLINE PLC Form 6-K July 13, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 13 July 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') Transaction notification

	Details of PDMR/person closely associa Name	ted with them ('PCA') Ms E Walmsley
	Position/status	Chief Executive Officer
c) 2.	Initial notification/ amendment Details of the issuer, emission allowance	Initial notification e market participant, auction
a)	LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.7040 16
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2018-07-12
f)	Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a)	Name	Mr R G Connor
h)	b) Position/statusc) Initial notification/	President, Global
a)		Manufacturing & Supply Initial notification
-)	amendment	an allowance market participant quatic

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.7040 59
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2018-07-12
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr S Dingemans	
b)	Position/status	Chief Financial Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction	
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to be repeated for (i) each type of		
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
	place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.	

c) Price(s) and volume(s)	Price(s) Volume(s) £15.7040 21
d) Aggregated information Aggregated volume Price	n/a (single transaction)
e) Date of the transaction	2018-07-12
f) Place of the transaction	London Stock Exchange (XLON)

1.	. Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr N Hirons	
b)	Position/status	SVP, Global Ethics &	
0)	Position/status	Compliance	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction	
a)	Name	GlaxoSmithKline plc	
b)	LEI	5493000HZTVUYLO1D793	
	Details of the transaction(s): section to b	e repeated for (i) each type of	
3.	3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
	place where transaction(s) has been cond	lucted	
		Ordinary shares of 25 pence	
	Description of the financial instrument	each ('Ordinary Shares')	
a)	Description of the financial instrument	ISIN: GB0009252882	
		Acquisition of Ordinary	
		Shares following the	
		re-investment of dividends	
b)	Nature of the transaction	paid to shareholders on 12	
0)	Nature of the transaction	July 2018, on shares held	
		through the Company's Share	
		Reward Plan.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.7040 10	
	A gamagatad information	10 10	
d)	Aggregated information	n/a (single transaction)	
. `	Aggregated volume Price	2019 07 12	
e)	Date of the transaction	2018-07-12	
f)	Place of the transaction	London Stock Exchange	
/		(XLON)	

a)	Name	Mr L Miels
		President, Global
b)	Position/status	Pharmaceuticals
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction
,	Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each
	place where transaction(s) has been cone	
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15,7040 1
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2018-07-12
f)	Place of the transaction	London Stock Exchange (XLON)

Details of PDMR/person closely associated with them ('PCA')		
Name	Mr D S Redfern	
Position/status	Chief Strategy Officer	
Initial notification/ amendment	Initial notification	
Details of the issuer, emission allowance	e market participant, auction	
platform, auctioneer or auction monitor		
Name	GlaxoSmithKline plc	
LEI	5493000HZTVUYLO1D793	
Details of the transaction(s): section to be repeated for (i) each type of		
instrument; (ii) each type of transaction; (iii) each date; and (iv) each		
place where transaction(s) has been conducted		
—		
	each ('Ordinary Shares')	
	Name Position/status Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction;	

ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £15.7040 68
d) Aggregated information Aggregated volume Price	n/a (single transaction)
e) Date of the transaction	2018-07-12
f) Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associa	ted with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market participant, auction
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
	Details of the transaction(s): section to b	e repeated for (i) each type of
3.	instrument; (ii) each type of transaction;	(iii) each date; and (iv) each
	place where transaction(s) has been cond	lucted
		Ordinary shares of 25 pence
a)	Description of the financial instrument	each ('Ordinary Shares')
<i>a)</i>	Description of the financial instrument	ISIN: GB0009252882
		Acquisition of Ordinary
		Shares following the
		re-investment of dividends
b)	Nature of the transaction	paid to shareholders on 12
		July 2018, on shares held
		through the Company's Share
		Reward Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s)
0)	Thee(s) and volume(s)	£15.7040 68
d)	Aggregated information	n/a (single transaction)
	Aggregated volume Price	
e)		
f)	Place of the transaction	London Stock Exchange
		(XLON)
	Date of the transaction	2018-07-12 London Stock Evolution
± \		U

1. a)	Details of PDMR/person closely associa Name	ils of PDMR/person closely associated with them ('PCA') e Mr P C Thomson	
b)	Position/status	President, Gl	obal Affairs
c)	Initial notification/ amendment	Initial notific	ation
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market partic	ipant, auction
a)	Name	GlaxoSmithK	Cline plc
	LEI		VUYLO1D793
0)	Details of the transaction(s): section to b		
3	instrument; (ii) each type of transaction;	•	••
0.	place where transaction(s) has been cond		, and (11) cach
			res of 25 pence
		each ('Ordina	•
a)	Description of the financial instrument	ISIN: GB000	•
			202002
		Acquisition c	of Ordinary
		Shares following the	
		re-investment of dividends	
b)	Nature of the transaction	paid to shareholders on 12	
		July 2018, on shares held	
		through the Company's Share	
		Reward Plan.	1 2
		Price(s)	Volume(s)
c)	Price(s) and volume(s)	£15.7040	38
	Aggregated information		
d)	Aggregated volume Price	n/a (single tra	ansaction)
e)	Date of the transaction	2018-07-12	
	Place of the transaction	London Sloci	k Exchange
c) f)	Place of the transaction	London Stock (XLON)	k Exchange

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte
- b) Position/status Company Secretary Initial notification/
- c) amendment Initial notification
- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc

b) 3.	LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction;		
	place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 July 2018, on shares held through the Company's Share Reward Plan.	
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.7040 49	
d)	Aggregated information Aggregated volume Price	n/a (single transaction)	
e)	Date of the transaction	2018-07-12	
f)	Place of the transaction	London Stock Exchange (XLON)	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: July 13, 2018

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc